Myriad Genetics
Molecular diagnostics business and drug development
Myriad Genetics was founded in 1991. The company also includes Myriad Genetic Laboratories, Inc. and Myriad Pharmaceuticals. Myriad Pharmaceuticals is involved in the identification of novel drug targets, the discovery of lead molecules, the development of drug candidates as well as the design and execution of clinical programmes.
Peter D. Meldrum (President and CEO)
Mark H. Skolnick (CSO)
John T. Henderson (Chairman)
Walter Gilbert (Vice Chairman)
Peter D. Meldrum
Gerald P. Belle
Robert S. Attiyeh
Dennis Langer
Mark H. Skolnick
Linda S. Wilson
320 Wakara Way
Salt Lake City, UT 84108
USA
Phone: +1-801-584-3600
Fax: +1-801-584-3640
Related patents
- Screening methods and sequences relating thereto
- Mass spectrometry to assess DNA sequence polymorphisms
- Screen assay for selecting protein-protein interaction modulators
- Enzyme assay and use thereof
- Method of detecting large genomic rearrangements
- Method, system and computer program product for providing a DNA STR profile
Related news
- Myriad Genetics Acquires Exclusive Rights to RAD51C Gene
- Myriad Genetics Makes Strategic Debt Investment With Exclusive Option to Acquire Crescendo Bioscience
- Myriad Announces New $100 Million Share Repurchase Program
- Myriad Genetics Announces Completion of Spin Off of Its Research and Pharmaceutical Business
- Myriad Genetics Announces Preliminary Revenue Results for Fiscal 2009 Fourth Quarter, Full Year
- Myriad Genetics Reports Fiscal 2009 Third Quarter Financial Results